Which Pharma Companies Are Dx Ready For Precision Medicine in 2017? Benchmarking, Financial Risks and Predictions - Diaceutics
+

Which Pharma Companies Are Dx Ready For Precision Medicine in 2017? Benchmarking, Financial Risks and Predictions

December 20th, 2016

Ewelina Golebiewska
Steve Vitale
Ryan Keeling


For the 2017 Pharma Readiness for Dx Index, Diaceutics applies analyses to 23 companies and examines the precision medicine (PM) credentials of over 1000 therapies on the market and in the pipeline, providing a 360° view of Dx-dependent therapy (Rx) assets. We include Big Data and lab partnerships alongside Rx/Dx partnerships to reflect the evolution of PM beyond molecular testing? and make considered predictions for the industry as it develops.

Listen to the webinar to learn:

  • What’s new in this year’s Pharma Readiness for Dx report
  • How the diagnostic market is currently placed and where it is heading in 2017 and beyond
  • How pharma readiness and financial risks can impact the industry

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

October 21st, 2019
Pharma Precision Medicine Readiness Report 2019
March 16th, 2018
PM Readiness Report 2018 Summary
View all reports

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications